Prognostic Role of Endocan and Platelet-Derived Growth Factor Isoforms in Metastatic Colorectal Cancer
Authors:
- Anıl YıldızAYAnıl Yıldız
- Melin Aydan AhmedMAMelin Aydan Ahmed
- Abdulmunir AzizyAAAbdulmunir Azizy
- Simay ÇokgezerSÇSimay Çokgezer
- Bedirhan UluferBUBedirhan Ulufer
- Hilal Oğuz SoydinçHSHilal Oğuz Soydinç
- Sanem KarabulutSKSanem Karabulut
- Didem TaştekinDTDidem Taştekin
- Burak ŞakarBŞBurak Şakar
- Naziye AkNANaziye Ak
Open Access
- 12 March 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (6) , 2600
Abstract
To investigate whether pretreatment serum endocan, platelet-derived growth factor (PDGF)-CC, and -DD levels are elevated in metastatic colorectal cancer (mCRC) patients compared to healthy controls, and to assess their independent associations with chemotherapy response and survival, along with their comparative predictive performance. Adult patients with mCRC receiving systemic chemotherapy combined with an anti-angiogenic agent (bevacizumab or aflibercept) were prospectively enrolled, along with healthy controls. Pretreatment serum samples were collected prior to therapy initiation. Endocan, PDGF-CC, and PDGF-DD levels were measured in duplicate using enzyme-linked immunosorbent assay. Treatment response was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and categorized as responders (complete or partial response) and non-responders (stable or progressive disease). Progression-free survival (PFS) and overall survival (OS) were recorded. Median serum levels of endocan (405.5 vs. 269.0 pg/mL), PDGF-DD (499.9 vs. 315.1 pg/mL), and PDGF-CC (2330 vs. 1118 pg/mL) were significantly higher in the mCRC group compared to controls (p < 0.001). In multivariable logistic regression, all three biomarkers were independently associated with non-response to chemotherapy [Odds ratio (ORs): 1.10 for endocan, 1.05 for PDGF-DD, 1.05 for PDGF-CC; all p < 0.05]. For disease progression, Cox regression showed that higher levels of endocan [Hazard ratio (HR) = 1.04], PDGF-DD (HR = 1.03), and PDGF-CC (HR = 1.04) were significant predictors (all p < 0.01). Similar associations were observed for overall mortality (HR = 1.04, 1.02, and 1.02, respectively; all p < 0.05). Endocan, PDGF-DD, and PDGF-CC are elevated in mCRC and independently predict poor treatment response and adverse survival outcomes, highlighting their potential as prognostic biomarkers.Keywords
Funding Information
- Scientific Research Projects Coordination Unit of Istanbul University Rectorate (TSA-2020-TSA-37036)
This publication has 38 references indexed in Scilit:
- Plasma Proteomic Profiling of Colorectal Cancer: Insights from Minimally Invasive Surgical CohortsJournal of Proteome Research, 2025
- Metabolic Reprogramming in Lung Cancer: Hallmarks, Mechanisms, and Targeted Strategies to Overcome Immune ResistanceCancer Medicine, 2025
- Endothelial cell heterogeneity in colorectal cancer: tip cells drive angiogenesisCellular and Molecular Life Sciences, 2024
- Functional and clinical roles of stromal PDGF receptors in tumor biologyCancer and Metastasis Reviews, 2024
- Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinomaBiochemical and Biophysical Research Communications, 2023
- Reversible promoter demethylation of PDGFD confers gemcitabine resistance through STAT3 activation and RRM1 upregulationCancer Letters, 2023
- Angiogenic signaling pathways and anti-angiogenic therapy for cancerSignal Transduction and Targeted Therapy, 2023
- 59P Platelet-derived growth factor (PDGF)-CC serum as clinical outcome predictor after six cycles of chemotherapy in colorectal cancer at RSMH PalembangAnnals of Oncology, 2022
- Proteoglycan Endocan: A multifaceted therapeutic target in CancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022
- Gastric cancer-derived MSC-secreted PDGF-DD promotes gastric cancer progressionJournal of Cancer Research and Clinical Oncology, 2014